Immunic Advances Vidofludimus Calcium in MS with Key Milestones Achieved in 2025

Immunic, Inc. (NASDAQ: IMUX) made meaningful progress in 2025 toward advancing vidofludimus calcium as a potential treatment for relapsing multiple sclerosis (RMS), highlighted by the completion of patient enrollment in both Phase 3 ENSURE trials. With enrollment now closed, the program is positioned to deliver synchronized top-line results in late 2026, a key catalyst that could materially shape Immunic’s outlook.

Phase 3 ENSURE Trials Fully Enrolled

The ENSURE-1 and ENSURE-2 trials randomized more than 2,200 patients across over 100 global clinical sites, underscoring the scale and rigor of the program. Management emphasized confidence that the studies are designed to comprehensively evaluate vidofludimus calcium’s effectiveness and safety in RMS.

The drug’s differentiating thesis remains its dual mechanism of action, combining selective DHODH inhibition with a proposed direct neuroprotective effect—a positioning that could be particularly relevant in a market where long-term disability outcomes increasingly drive clinical and commercial differentiation.

Long-Term Data Reinforces Disability Profile

Supporting the Phase 3 effort is the company’s long-term EMPhASIS open-label extension experience. Extended follow-up data has shown low rates of confirmed disability worsening alongside a favorable safety profile, reinforcing Immunic’s belief that vidofludimus calcium may impact both inflammation-driven relapses and long-term functional decline.

Progressive MS Data De-Risks Expansion Strategy

Beyond RMS, Immunic continues to build a potential roadmap into progressive MS (PMS)—a segment with significant unmet need and clearer regulatory precedents. Phase 2 CALLIPER results strengthened confidence in the neuroprotective hypothesis, demonstrating reductions in 24-week confirmed disability worsening and statistically significant improvements across key disability metrics. Collectively, these results may support future late-stage development discussions with regulators.

Pipeline Optionality: IMU-856

Immunic also highlighted early promise for IMU-856, particularly in celiac disease, broader gastrointestinal disorders, and weight management. However, management has indicated that further advancement of IMU-856 will depend on financing capacity or strategic partnerships, positioning the program as longer-dated optionality rather than a near-term value driver.

Financials and Valuation: Target Adjusted to $8

Immunic recently reduced its price target from $10.00 to $8.00, reflecting expectations of future dilution as the company funds its Phase 3 MS program. In 2025, Immunic raised approximately $70 million through public offerings, but cash burn remains meaningful with quarterly expenses including:

• R&D: ~$20M

• G&A: ~$6M

Valuation models incorporate a 30% probability of success for MS, a 30% discount rate, and assumptions for additional capital raises, resulting in a 12-month target of $8.00.

Upcoming Catalysts

The next major catalysts for Immunic include:

• Potential interim updates on the ENSURE program

• The anticipated Phase 3 ENSURE readout in late 2026

• Potential regulatory discussions based on CALLIPER data in progressive MS

These events could serve as key inflection points for sentiment, valuation, and partnership potential.

Key Risks

Despite progress, Immunic remains exposed to a broad range of risks including:

• Clinical and regulatory uncertainty

• Financing and dilution pressure

• Commercial competition and market share constraints

• Intellectual property durability and lifecycle execution

Still, the company’s 2025 milestones—most notably full Phase 3 enrollment—represent a major step forward in its effort to deliver an innovative MS therapy with potential relevance across both relapsing and progressive disease segments.

For more information on Immunic Inc. please visit www.imux.com.